Peter Dillon
Research Subjects
Peter Dillon has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Gary R. Jones
From the Department of Surgery, Division of Pediatric Surgery, Penn State College of Medicine, Hershey; Department of Surgery, Children's Hospital of Pittsburgh, Pittsburgh, PA; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Oregon Health Sciences University, Portland, OR; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA; Department of Pediatric Surgery, The Children's Hospital, Denver, CO
2 shared publicationsAllison Kempe
1 shared publicationElaine Morrato
1 shared publicationEugene S. Wiener
From the Department of Surgery, Division of Pediatric Surgery, Penn State College of Medicine, Hershey; Department of Surgery, Children's Hospital of Pittsburgh, Pittsburgh, PA; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Oregon Health Sciences University, Portland, OR; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA; Department of Pediatric Surgery, The Children's Hospital, Denver, CO
1 shared publicationGerald M. Haase
From the Department of Surgery, Division of Pediatric Surgery, Penn State College of Medicine, Hershey; Department of Surgery, Children's Hospital of Pittsburgh, Pittsburgh, PA; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Oregon Health Sciences University, Portland, OR; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA; Department of Pediatric Surgery, The Children's Hospital, Denver, CO
1 shared publicationHolly A. Bagnall-Reeb
From the Department of Surgery, Division of Pediatric Surgery, Penn State College of Medicine, Hershey; Department of Surgery, Children's Hospital of Pittsburgh, Pittsburgh, PA; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Oregon Health Sciences University, Portland, OR; Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA; Department of Pediatric Surgery, The Children's Hospital, Denver, CO
1 shared publication
Latest Publications
- 1 May 2008
- Published by Elsevier in Seminars in Pediatric Surgery
- Vol. 17 (2) , 131-140
Developing a NSQIP module to measure outcomes in children’s surgical care: opportunity and challenge
- 1 May 2008
- Published by Elsevier in Seminars in Pediatric Surgery
- Vol. 17 (2) , 131-140
Developing a NSQIP module to measure outcomes in children’s surgical care: opportunity and challenge
- 1 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (13) , 2718-2723
Prophylactic Urokinase in the Management of Long-Term Venous Access Devices in Children: A Children's Oncology Group Study
Purpose Infection and thrombosis are serious complications of long-term vascular access devices in children undergoing chemotherapy. Since routine fibrinolytic therapy may decrease these complications, the purpose of this study was to compare the efficacy of an every-2-week administration of urokinase with standard heparin flushes in reducing the incidence of device-related infections and occlusions. Materials and Methods This study was a prospective, randomized phase III multicenter trial conducted by the Children's Cancer Group, in which patients with implantable ports or tunneled catheters received either urokinase or heparin every 2 weeks for 12 months. Study end points were time to first occlusion or time to first device-related infection. Results Five hundred seventy-seven patients from 29 institutions were enrolled, of whom 51% had external catheters and 49% had ports. Urokinase administration resulted in fewer occlusive events than heparin (23% v 31%; P = .02), a longer time to first occlusive event (log-rank analysis, P = .006), and a 1.6-fold difference in the rate of occlusive events (Poisson regression, P = .003). Similar results were noted when comparing ports and tunneled catheters. The urokinase group also had a 1.4-fold difference in the rate of infection (Poisson regression, P = .05) and longer time to first infection (log-rank, P = .07), but the difference was significant only in tunneled catheters. Conclusion Urokinase administration every 2 weeks significantly affects the rate of occlusive events in ports and tunneled catheters and of infectious events in external catheters compared with heparin administration.
- 1 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (13) , 2718-2723
Prophylactic Urokinase in the Management of Long-Term Venous Access Devices in Children: A Children's Oncology Group Study
Purpose Infection and thrombosis are serious complications of long-term vascular access devices in children undergoing chemotherapy. Since routine fibrinolytic therapy may decrease these complications, the purpose of this study was to compare the efficacy of an every-2-week administration of urokinase with standard heparin flushes in reducing the incidence of device-related infections and occlusions. Materials and Methods This study was a prospective, randomized phase III multicenter trial conducted by the Children's Cancer Group, in which patients with implantable ports or tunneled catheters received either urokinase or heparin every 2 weeks for 12 months. Study end points were time to first occlusion or time to first device-related infection. Results Five hundred seventy-seven patients from 29 institutions were enrolled, of whom 51% had external catheters and 49% had ports. Urokinase administration resulted in fewer occlusive events than heparin (23% v 31%; P = .02), a longer time to first occlusive event (log-rank analysis, P = .006), and a 1.6-fold difference in the rate of occlusive events (Poisson regression, P = .003). Similar results were noted when comparing ports and tunneled catheters. The urokinase group also had a 1.4-fold difference in the rate of infection (Poisson regression, P = .05) and longer time to first infection (log-rank, P = .07), but the difference was significant only in tunneled catheters. Conclusion Urokinase administration every 2 weeks significantly affects the rate of occlusive events in ports and tunneled catheters and of infectious events in external catheters compared with heparin administration.
- 1 April 2002
- Published by SAGE Publications in Journal of Pediatric Oncology Nursing
- Vol. 19 (2) , 48-49
Urokinase for prevention of central venous catheter occlusions and infections: Results of the Children's Cancer Group study CCG-S921
- 1 April 2002
- Published by SAGE Publications in Journal of Pediatric Oncology Nursing
- Vol. 19 (2) , 48-49
Urokinase for prevention of central venous catheter occlusions and infections: Results of the Children's Cancer Group study CCG-S921